ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Efficacy of Sublingual Midazolam in Association With Oral Morphine in Children Analgesia After Bone Fracture (MIDAZODOL)

This study is currently recruiting participants.
Verified by Assistance Publique - Hôpitaux de Paris, August 2008

Sponsored by: Assistance Publique - Hôpitaux de Paris
Information provided by: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT00416039
  Purpose

It is a randomized simple-blind monocentric study; the group A will receive oral morphine with placebo and the group B will receive oral morphine with sublingual midazolam. The aim of this study is to show a more important pain decrease in the group taking midazolam versus placebo.


Condition Intervention Phase
Fractures
Drug: Midazolam
Drug: Placebo
Phase III

MedlinePlus related topics:   Fractures   

Drug Information available for:   Midazolam    Midazolam hydrochloride    Midazolam maleate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:   Clinical Randomized Study of Sublingual Midazolam in Association With Morphine by Oral Route in Arm Fracture in Children at the Emergency Children Care

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • Difference in the measurement of pain analogical scale values at 30 minutes between the two groups [ Time Frame: after administration until 120 minutes ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pain Analogical scale Values at 15, 30 minutes, 1 hour, 1h30 and 2 hours. [ Time Frame: after administration until 120 minutes ] [ Designated as safety issue: Yes ]
  • Pain Analogical scale Values after the treatment of the fracture [ Time Frame: after administration until 120 minutes ] [ Designated as safety issue: Yes ]
  • Respiratory rate, Oxymetry [ Time Frame: after administration until 120 minutes ] [ Designated as safety issue: Yes ]
  • Conscience (lethargy or irritability) [ Time Frame: after administration until 120 minutes ] [ Designated as safety issue: Yes ]
  • nausea, [ Time Frame: after administration until 120 minutes ] [ Designated as safety issue: Yes ]
  • skin hyperesthesia, rash [ Time Frame: after administration until 120 minutes ] [ Designated as safety issue: Yes ]
  • children cooperation [ Time Frame: after surgical procedure ] [ Designated as safety issue: No ]

Estimated Enrollment:   60
Study Start Date:   January 2007
Estimated Study Completion Date:   February 2009
Estimated Primary Completion Date:   November 2008 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
1: Experimental
Midazolam and morphine
Drug: Midazolam
0.2 mg/kg of sublingual midazolam and 0.5 mg/kg of morphine
2: Placebo Comparator
placebo, Nacl 0.9 %, morphine 0.5 mg/kg
Drug: Placebo
placebo at 0.2 mg/kg and morphine 0.5 mg/kg

Detailed Description:

Fracture is often responsible of pain in the paediatric emergency department (ED). This pain is very severe and needs effective drugs.

During a study made at the ED of Necker Enfants Malades Hospital, it has been shown that the oral morphine had a limited action on this kind of pain. Therefore it is interesting to increase the analgesia by making a drug association, for example with the midazolam witch is a benzodiazepine with a sedative and anxiolytic action, and which has got the MMA for the intravenous and the intra rectal forms for children older than 6 months.

The intravenous form has some disadvantages like an extra work and an increase of risk of side effects.

That is why the sublingual form seems to be interesting in this context. Even if some studies have shown the benefit of midazolam as a preanesthetic medication given to children scheduled for a surgical procedure, none has shown the interest of sublingual midazolam associated with oral morphine to relieve the pain due to a displaced fracture.

The aim of this study is to show a more important pain decrease in the group taking midazolam versus placebo.

It is a randomized simple-blind monocentric study; the group A will receive oral morphine with placebo and the group B will receive oral morphine with sublingual midazolam . The pain will be quantified thanks to the visual analogical scale (VAS)before and 30 minutes after the drugs administration, and we will try to show a difference of 15 points(on 100) of the VAS at 30 minutes between the two groups.

60 patients aged from 5 to 16 years old and having a displaced fracture will be enrolled in this study which will last 1 year.

Patients having a contra-indication for morphine and midazolam won't be enrolled as patients with femoral fracture which needs a local anaesthesia.

  Eligibility
Ages Eligible for Study:   5 Years to 16 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • children between 5 and 16 years old
  • children with a disjoined bone fracture
  • children needed oral morphine analgesia
  • written informed consent from one or the two parents or legal pad

Exclusion Criteria:

  • ASA score > 2
  • concomitant administration of oral analgesia (level II WHO classification) less than 6 hours
  • concomitant administration of benzodiazepine less than 24 hours
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00416039

Contacts
Contact: Christelle Wille, MD     +33(0)1 44 49 42 90     christelle.wille@nck.aphp.fr    
Contact: Gerard Cheron, MD,PhD     +33(0)1 44 49 48 99     gerard.cheron@nck.aphp.fr    

Locations
France
Hopital Necker enfants Malade - Department of Pediatric Emergency     Recruiting
      Paris, France, 75015
      Contact: Christelle Wille, MD     0144494290     christelle.wille@nck.aphp.fr    
      Contact: Gerard Cheron, MD, PhD     0144494899     gerard.cheron@nck.aphp.fr    
      Sub-Investigator: Christelle Wille, MD            
      Principal Investigator: Gerard Cheron, MD, PhD            

Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris

Investigators
Principal Investigator:     Gérard CHERON, MD, PhD     Assistance Publique - Hôpitaux de Paris    
  More Information


Responsible Party:   Department Clinical Research of Developpement ( Christophe Aucan )
Study ID Numbers:   P051033
First Received:   December 26, 2006
Last Updated:   September 5, 2008
ClinicalTrials.gov Identifier:   NCT00416039
Health Authority:   France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
midazolam  
sublingual  
oral morphine  
children
bone fracture
bone fracture with a deformed member

Study placed in the following topic categories:
Morphine
Fractures, Bone
Wounds and Injuries
Disorders of Environmental Origin
Emergencies
Midazolam

Additional relevant MeSH terms:
Anesthetics, Intravenous
Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
GABA Modulators
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Anesthetics
Narcotics
Pharmacologic Actions
Adjuvants, Anesthesia
Sensory System Agents
Anesthetics, General
Therapeutic Uses
Hypnotics and Sedatives
GABA Agents
Anti-Anxiety Agents
Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on October 22, 2008




Links to all studies - primarily for crawlers